Korro Bio KRRO 深 滬
等待開盤 11-07 09:30:00 美东时间
14.75
+0.020
+0.14%
華盛通- 最 高15.74
- 今 開14.74
- 成交量 12.26万股
- 最 低 14.69
- 昨 收 14.73
- 總市值 2.17亿
- 52周最高 17.3529
- 市盈率 靜 --
- 換手率 0.83%
- 52周最低 5.2044
- 委 比 -77.78%
- 總股本 1472.56万
- 歷史最高 2918.50
- 量 比 0.42
- 振 幅 7.13%
- 歷史最低 5.2044
- 每 手 1
- 風險率 3.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Korro Bio shares are trading lower after the company disclosed that Novo Nordisk plans to terminate their collaboration and licensing agreement, effective February 1, 2027.
Korro Bio shares are trading lower after the company disclosed that Novo Nordisk plans to terminate their collaboration and licensing agreement, effective February 1, 2027.
11-06 02:01
Korro Bio Q3 EPS $(0.98) Beats $(1.26) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.26) by 22.22 percent. This is a 48.96 percent increase over losses of $(1.92) per share from the same period last year.
11-05 21:03
“我低估了中国管线” ，全球RNAi拓荒者透视中国小核酸产业
（来源：动脉新医药） 撰稿｜武瑛港 编者按 BD从未像今天这样重要，也从未像今天这样复杂。License-in退潮，License-out屡创纪录，NewCo快...
10-27 08:00
Korro Bio Announces Preclinical Results Showing KRRO-111 Potential To Treat Both Lung And Liver Manifestations Of Alpha-1 Antitrypsin Deficiency
Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold KRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%, highlighting its potential to reduce toxic protein accumulation in the liver Best-in-class p...
10-22 19:11
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
Korro Bio announced preclinical results for KRRO-111, a potential treatment for alpha-1 antitrypsin deficiency (AATD). The study showed KRRO-111 restored functional M-AAT, reduced toxic Z-AAT by up to 95%, and achieved sustained RNA editing. It demonstrated the potential to address both lung and liver manifestations of AATD. Regulatory submission is expected in the first half of 2027.
10-22 11:00
美股大行评级 | 花旗看高AMD至800美元！富国上调Meta目标价至1000美元
今日重点评级关注：Jones Trading：维持Opus Genetics"买入"评级，目标价从10美元升至17美元；Citizens：维持Rezolute"跑赢大市"评级，目标价从11美元升至15美元
10-07 17:30
Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, announced today that the first cohort of participants has be...
10-06 04:10
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Korro Bio has initiated a Phase 1/2 clinical trial for KRRO-121, an RNA-editing oligonucleotide targeting hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE). The trial, named ANCHOR, includes two parts: Part 1 evaluates safety and pharmacokinetics in healthy volunteers, with the first cohort dosed at 2mg/kg. Part 2 will assess safety, tolerability, and clinical activity in UCD patients, expected to begin d...
10-05 20:05
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio granted nonstatutory stock options to three new employees, allowing them to purchase 5,000 shares at $12.93 per share. The options vest over four years and were approved under the 2026 Inducement Plan. Korro, a biopharmaceutical company, uses its OPERA platform to develop genetic medicines targeting rare and prevalent diseases by editing RNA for precise and transient single base edits.
09-11 20:05
Korro to Participate in Upcoming Investor Conferences
Korro Bio, Inc. (KRRO) announced that its CEO, Ram Aiyar, will participate in two investor conferences: the Citi 2026 Biopharma Back to School Summit on September 9th and the 2026 Cantor Global Healthcare Conference on September 10th. Korro, a biopharmaceutical company, utilizes its OPERA® platform to develop RNA-editing therapies for rare and prevalent diseases. The platform enables precise, transient mRNA modifications to enhance protein functi...
08-27 11:00
